Carna Biosciences, Inc.
TSE:4572.T
308 (JPY) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,625.889 | 1,386.748 | 2,017.529 | 1,133.346 | 3,207.423 | 754.691 | 657.516 | 811.598 | 1,569.205 | 611.76 | 771.464 | 510.829 | 592.549 | 571.8 | 687.013 | 499.57 |
| Cost of Revenue
| 175.293 | 171.55 | 135.387 | 192.149 | 207.59 | 250.699 | 222.502 | 254.425 | 269.594 | 232.956 | 232.114 | 210.371 | 202.045 | 201.832 | 215.768 | 122.99 |
| Gross Profit
| 1,450.596 | 1,215.198 | 1,882.142 | 941.197 | 2,999.833 | 503.992 | 435.014 | 557.173 | 1,299.611 | 378.804 | 539.35 | 300.458 | 390.504 | 369.968 | 471.245 | 376.58 |
| Gross Profit Ratio
| 0.892 | 0.876 | 0.933 | 0.83 | 0.935 | 0.668 | 0.662 | 0.687 | 0.828 | 0.619 | 0.699 | 0.588 | 0.659 | 0.647 | 0.686 | 0.754 |
| Reseach & Development Expenses
| 1,903.859 | 1,882.319 | 1,841.854 | 1,474.452 | 1,281.98 | 1,140.841 | 670.861 | 513.43 | 417.249 | 561 | 423 | 376 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103 | 0 | 0 | 62 | 64 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 364.719 | 0 | 0 | 346 | 318 | 0 | 0 | 0 | 0 |
| SG&A
| 2,567.574 | 602.767 | 571.423 | 523.812 | 740.075 | 507.67 | 463.213 | 467.719 | 409.581 | 416 | 408 | 382 | 0 | 0 | 0 | 0 |
| Other Expenses
| -0.517 | 2,485.086 | 2,413.277 | 1,998.264 | 2,022.055 | -1.185 | 4.596 | 8.916 | 30.253 | 25.734 | 25.685 | 19.083 | 59.36 | 33.634 | 0.967 | -37.348 |
| Operating Expenses
| 2,567.574 | 2,485.086 | 2,413.277 | 1,998.264 | 2,022.055 | 1,648.511 | 1,134.074 | 981.149 | 826.829 | 1,013.753 | 840.051 | 758.3 | 783.743 | 768.153 | 815.523 | 672.844 |
| Operating Income
| -1,116.978 | -1,269.889 | -531.136 | -1,057.068 | 977.778 | -1,144.519 | -699.06 | -423.977 | 472.781 | -634.949 | -300.7 | -457.842 | -393.239 | -398.185 | -344.278 | -296.264 |
| Operating Income Ratio
| -0.687 | -0.916 | -0.263 | -0.933 | 0.305 | -1.517 | -1.063 | -0.522 | 0.301 | -1.038 | -0.39 | -0.896 | -0.664 | -0.696 | -0.501 | -0.593 |
| Total Other Income Expenses Net
| -13.868 | -53.51 | -1.363 | -45.419 | -64.719 | -62.28 | -34.319 | 135.05 | 13.308 | -209.887 | 21.698 | 9.878 | 38.064 | 3.422 | 31.225 | -205.771 |
| Income Before Tax
| -1,130.846 | -1,323.399 | -532.499 | -1,102.487 | 913.059 | -1,206.799 | -733.38 | -288.926 | 486.09 | -844.836 | -279.003 | -447.964 | -355.175 | -394.763 | -313.053 | -502.035 |
| Income Before Tax Ratio
| -0.696 | -0.954 | -0.264 | -0.973 | 0.285 | -1.599 | -1.115 | -0.356 | 0.31 | -1.381 | -0.362 | -0.877 | -0.599 | -0.69 | -0.456 | -1.005 |
| Income Tax Expense
| 22.048 | 26.14 | 1.975 | 8.545 | 84.77 | 3.773 | 3.883 | 1.014 | 29.701 | 1.881 | 3.34 | 2.029 | 6.476 | 2.344 | 2.344 | 1.004 |
| Net Income
| -1,152.895 | -1,349.539 | -534.474 | -1,111.032 | 828.289 | -1,210.573 | -737.264 | -289.94 | 456.388 | -846.717 | -282.343 | -449.994 | -361.651 | -397.107 | -315.397 | -503.039 |
| Net Income Ratio
| -0.709 | -0.973 | -0.265 | -0.98 | 0.258 | -1.604 | -1.121 | -0.357 | 0.291 | -1.384 | -0.366 | -0.881 | -0.61 | -0.694 | -0.459 | -1.007 |
| EPS
| -68.62 | -99.1 | -42.1 | -90.33 | 76.05 | -125.02 | -78.53 | -31.64 | 52.61 | -102.18 | -36.59 | -73.28 | -61.6 | -67.64 | -58.74 | -98.14 |
| EPS Diluted
| -68.62 | -99.1 | -42.1 | -90.33 | 74.51 | -125.02 | -78.53 | -31.64 | 50.05 | -102.18 | -36.59 | -73.28 | -61.6 | -67.64 | -58.74 | -98.14 |
| EBITDA
| -1,081.366 | -1,241.66 | -499.903 | -1,057.314 | 974.718 | -1,135.88 | -692.481 | -413.197 | 513.739 | -537.345 | -236.79 | -401.028 | -299.448 | -305.42 | -248.034 | -293.934 |
| EBITDA Ratio
| -0.665 | -0.895 | -0.248 | -0.933 | 0.304 | -1.505 | -1.053 | -0.509 | 0.327 | -0.878 | -0.307 | -0.785 | -0.505 | -0.534 | -0.361 | -0.588 |